Integrative Analysis of Transcriptomic and Metabolomic Profiles Reveals Enhanced Arginine Metabolism in Androgen-independent Prostate Cancer Cells

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2023 Dec 16

PMID 38104097

Authors

Xingchen Dai

Xinyi Shi

Mingxiu Luo

Pu Li

Yujing Gao

Affiliations

Soon will be listed here.

Abstract

Background: Prostate cancer is a common solid tumor that affects a significant number of men worldwide. Conventional androgen deprivation therapy (ADT) increases the risk of developing castration-resistant prostate cancer (CRPC). Effective clinical management of patients with CRPC is challenging due to the limited understanding.

Methods: In this study, transcriptomic and metabolomic profiles of androgen-dependent prostate cancer cell line LNCaP and the androgen-independent cells developed from LNCaP cells (LNCaP-ADR) were investigated using RNA-sequencing and LC-MS/MS, respectively. The differentially expressed genes and metabolites were analyzed, and integrative analysis of transcriptomic and metabolomic data was further conducted to obtain a comprehensive understanding of the metabolic characteristics in LNCaP-ADR cells. Quantitative real-time PCR (QPCR) was employed to ascertain the mRNA expression levels of the selected differentially expressed genes.

Results: The arginine and proline metabolism pathway was identified as a commonly altered pathway at both the transcriptional and metabolic levels. In the LNCaP-ADR cells, significant upregulation was observed for metabolites including 5-Aminopentanoic acid, L-Arginine, L-Glutamic acid, N-Acetyl-L-alanine, and Pyrrole-2-carboxylic acid at the metabolic level. At the transcriptional level, MAOA, ALDH3A2, ALDH2, ARG1, CKMT2, and CNDP1 were found to be significantly upregulated in the LNCaP-ADR cells. Gene set enrichment analysis (GSEA) identified various enriched gene sets in the LNCaP-ADR cells, encompassing inflammatory response, 9plus2 motile cilium, motile cilium, ciliary plasm, cilium or flagellum-dependent cell motility, cilium movement, cilium, response to endoplasmic reticulum stress, PTEN DN.V1 DN, SRC UP.V1 UP, IL15 UP.V1 DN, RB DN.V1 DN, AKT UP MTOR DN.V1 UP, VEGF A UP.V1 UP, and KRAS.LUNG.BREAST UP.V1 UP.

Conclusions: These findings highlight the substantial association between the arginine and proline metabolism pathway and CRPC, emphasizing the need to prioritize strategies that target dysregulated metabolites and differentially expressed genes as essential interventions in the clinical management of CRPC.

Citing Articles

Dietary phytochemical indole-3-carbinol regulates metabolic reprogramming in mouse prostate tissue.

Peter R, Sarwar M, Wang L, Chou P, Wang C, Wang Y Pharm Res. 2025; 42(2):237-247.

PMID: 39904853 PMC: 11880055. DOI: 10.1007/s11095-025-03820-8.

The prognostic and neuroendocrine implications of SLC25A29-mediated biomass signature in prostate cancer.

Wu C, Hu S, Dong S, Tzou K, Li C Geroscience. 2025; .

PMID: 39890746 DOI: 10.1007/s11357-025-01538-4.

Identification of pyrimidine metabolism-based molecular subtypes and prognostic signature to predict immune landscape and guide clinical treatment in prostate cancer.

Yu Y, Xie X, Cai M, Hong Y, Ren Y, Kang X Ann Med. 2025; 57(1):2449584.

PMID: 39803822 PMC: 11731156. DOI: 10.1080/07853890.2025.2449584.

CNDP1 Suppresses the Malignant Behavior of Hepatoma Cell Restricting PI3K-AKT-mTOR Activation.

Du Y, Pan L, Zhang W, Wei S, Fan X, Zhang N Curr Cancer Drug Targets. 2024; 25(2):131-143.

PMID: 39229979 DOI: 10.2174/0115680096332450240827070033.

Metabolomics and Proteomics in Prostate Cancer Research: Overview, Analytical Techniques, Data Analysis, and Recent Clinical Applications.

Al-Daffaie F, Al-Mudhafar S, Alhomsi A, Tarazi H, Almehdi A, El-Huneidi W Int J Mol Sci. 2024; 25(10).

PMID: 38791108 PMC: 11120916. DOI: 10.3390/ijms25105071.

References

Dwivedi S, Goel A, Khattri S, Mandhani A, Sharma P, Misra S . Genetic variability at promoters of IL-18 (pro-) and IL-10 (anti-) inflammatory gene affects susceptibility and their circulating serum levels: An explorative study of prostate cancer patients in North Indian populations. Cytokine. 2015; 74(1):117-22. DOI: 10.1016/j.cyto.2015.04.001. View

Zhao Y, Cheng X, Vaziri N, Liu S, Lin R . UPLC-based metabonomic applications for discovering biomarkers of diseases in clinical chemistry. Clin Biochem. 2014; 47(15):16-26. DOI: 10.1016/j.clinbiochem.2014.07.019. View

Omlin A, Pezaro C, Mukherji D, Mulick Cassidy A, Sandhu S, Bianchini D . Improved survival in a cohort of trial participants with metastatic castration-resistant prostate cancer demonstrates the need for updated prognostic nomograms. Eur Urol. 2013; 64(2):300-6. DOI: 10.1016/j.eururo.2012.12.029. View

Gaunitz F, Hipkiss A . Carnosine and cancer: a perspective. Amino Acids. 2012; 43(1):135-42. DOI: 10.1007/s00726-012-1271-5. View

Tousignant K, Rockstroh A, Fard A, Lehman M, Wang C, McPherson S . Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis. Mol Cancer Res. 2019; 17(5):1166-1179. DOI: 10.1158/1541-7786.MCR-18-1147. View

Chantranupong L, Scaria S, Saxton R, Gygi M, Shen K, Wyant G . The CASTOR Proteins Are Arginine Sensors for the mTORC1 Pathway. Cell. 2016; 165(1):153-164. PMC: 4808398. DOI: 10.1016/j.cell.2016.02.035. View

Wen F, Huang J, Lu X, Huang W, Wang Y, Bai Y . Identification and prognostic value of metabolism-related genes in gastric cancer. Aging (Albany NY). 2020; 12(17):17647-17661. PMC: 7521523. DOI: 10.18632/aging.103838. View

Jung K, Reszka R, Kamlage B, Bethan B, Stephan C, Lein M . Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. Int J Cancer. 2013; 133(12):2914-24. DOI: 10.1002/ijc.28303. View

Roberts M, Schirra H, Lavin M, Gardiner R . Metabolomics: a novel approach to early and noninvasive prostate cancer detection. Korean J Urol. 2011; 52(2):79-89. PMC: 3045724. DOI: 10.4111/kju.2011.52.2.79. View

10.

Sandhu S, Moore C, Chiong E, Beltran H, Bristow R, Williams S . Prostate cancer. Lancet. 2021; 398(10305):1075-1090. DOI: 10.1016/S0140-6736(21)00950-8. View

11.

Yin L, Li J, Wang J, Pu T, Wei J, Li Q . MAOA promotes prostate cancer cell perineural invasion through SEMA3C/PlexinA2/NRP1-cMET signaling. Oncogene. 2021; 40(7):1362-1374. PMC: 8604374. DOI: 10.1038/s41388-020-01615-2. View

12.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2022; 51(D1):D587-D592. PMC: 9825424. DOI: 10.1093/nar/gkac963. View

13.

Teahan O, Bevan C, Waxman J, Keun H . Metabolic signatures of malignant progression in prostate epithelial cells. Int J Biochem Cell Biol. 2010; 43(7):1002-9. DOI: 10.1016/j.biocel.2010.07.003. View

14.

Noonan-Wheeler F, Wu W, Roehl K, Klim A, Haugen J, Suarez B . Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. Prostate. 2005; 66(1):49-56. DOI: 10.1002/pros.20320. View

15.

Guey L, Garcia-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M . Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol. 2009; 57(2):283-92. PMC: 3220186. DOI: 10.1016/j.eururo.2009.08.001. View

16.

Schwenk J, Igel U, Neiman M, Langen H, Becker C, Bjartell A . Toward next generation plasma profiling via heat-induced epitope retrieval and array-based assays. Mol Cell Proteomics. 2010; 9(11):2497-507. PMC: 2984230. DOI: 10.1074/mcp.M110.001560. View

17.

Adekoya T, Richardson R . Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis. Int J Mol Sci. 2020; 21(12). PMC: 7352203. DOI: 10.3390/ijms21124449. View

18.

Gannon P, Godin-Ethier J, Hassler M, Delvoye N, Aversa M, Poisson A . Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS One. 2010; 5(8):e12107. PMC: 2920336. DOI: 10.1371/journal.pone.0012107. View

19.

Wang H, Tang M, Ou L, Hou M, Feng T, Huang Y . Biological analysis of cancer specific microRNAs on function modeling in osteosarcoma. Sci Rep. 2017; 7(1):5382. PMC: 5511279. DOI: 10.1038/s41598-017-05819-7. View

20.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View